Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 15, 2016 - Issue 2
Submit an article Journal homepage
247
Views
11
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

A Safety Evaluation of Cangrelor in Patients Undergoing PCI

Francesco FranchiDepartment of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA
,
Fabiana RolliniDepartment of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA
,
Yongwhi ParkDepartment of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA;Division of Cardiology, Gyeongsang National University Hospital, Jinju, Korea
&
Dominick J. AngiolilloDepartment of Medicine, Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USACorrespondence[email protected]
Pages 275-285 | Received 03 Nov 2015, Accepted 14 Dec 2015, Published online: 09 Jan 2016

References

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–2494.
  • Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74:597–607.
  • Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72:2087–2116.
  • Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12:30–47.
  • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516.
  • Michelson AD, Frelinger AL 3rd, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30:1753–1763.
  • Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456–1462.
  • Franchi F, Rollini F, Cho JR, et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv. 2015;8:1457–1467.
  • Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797–804.
  • Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601–1606.
  • Franchi F, Rollini F, Angiolillo DJ. Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Curr Opin Cardiol. 2014;29:553–563.
  • Capodanno D, Angiolillo DJ. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv. 2015;8:e002301.
  • Franchi F, Rollini F, Muñiz-Lozano A, et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013;11:1279–1291.
  • Hechler B, Vigne P, Léon C, et al. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol. 1998;53:727–733.
  • Ingall AH, Dixon J, Bailey A, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999;42:213–220.
  • Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005;31:195–204.
  • Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50:27–35.
  • Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85:401–407.
  • Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307:265–274.
  • Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34:44–55.

• Platelet function substudy of the CHAMPION PCI and PLATFORM trials. This is the largest study investigating pharmacodynamic profiles of cangrelor.

  • Nassim MA, Sanderson JB, Clarke C, et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers. J Am Coll Cardiol. 1999;33(2 Suppl A):A255.
  • Javis GE, Nassim MA, Humphries RG, et al. The P2Y antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood. 1999;94(Suppl. 1):A22.
  • Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3:85–92.
  • Rollini F, Franchi F, Tello-Montoliu A, et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc Interv. 2014;7:426–434.
  • Ferreiro JL, Ueno M, Tello-Montoliu A, et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. J Thromb Thrombolysis. 2013;35:155–164.
  • Greenbaum AB, Ohman EM, Gibson CM, et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J. 2007;154:702–709.

• Phase II study exploring safety and efficacy of cangrelor in patients with STEMI.

  • Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151:689.e1–689.e10.

• Phase II study exploring safety and efficacy of cangrelor in patients undergoing PCI.

  • Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318–2329.
  • Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330–2341.
  • White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:182-90.e4.

• Pooled analysis of the CHAMPION PCI and CHAMPION PLATFORM trials, which used the universal definition of MI and showed efficacy of cangrelor.

  • Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303–1313.

•• The largest Phase 3 clinical trials showing efficacy and safety of cangrelor in patients undergoing PCI.

  • Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014;63:619–629.
  • Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382:1981–1992.

•• Pooled analysis of the three CHAMPION trials, which used the universal definition to define MI events.

  • Cangrelor United States full prescribing information; [ cited 2015 Oct 29]. Available from: www.kengreal.com/pdfs/kengreal-us-prescribing-information.pdf
  • Cangrelor EMA prescribing information; [ cited 2015 Oct 29]. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003773/WC500188098.pdf
  • Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457–1466.
  • Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA. 2013;309:1022–1029.
  • Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–782.
  • Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–2747.
  • Kikkert WJ, Van Geloven N, Van Der Laan MH. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol. 2014;63:1866–1875.
  • Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012;125:1424–1431.
  • Gutierrez JA, Harrington RA, Blankenship JC, et al. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2015 [cited 2015 Sep 23]. doi:10.1093/eurheartj/ehv498.
  • Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009;53:2019–2027.
  • Muñiz-Lozano A, Rollini F, Franchi F, et al. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis. 2013;7:197–213.
  • Stone GW, Mehran R, Steg PG. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes. JACC Cardiovasc Interv. 2015;8:225–227.
  • White HD, Bhatt DL, Gibson CM, et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015;8:424–433.
  • Unverdorben M, Parodi G, Pistolesi M, et al. Dyspnea related to reversibly-binding P2Y12 inhibitors: a review of the pathophysiology, clinical presentation and diagnostics. Int J Cardiol. 2015;202:167–173.
  • Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63:2503–2509.
  • Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost. 2012;108:1031–1036.
  • Ranhosky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation. 1990;81:1205–1209.
  • Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108–3116.
  • Angiolillo DJ, Bhatt DL, Steg PG, et al. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis. 2015;40:317–322.

• Post hoc analysis of the CHAMPION trials evaluating the effects of cangrelor overdosing on safety.

  • Green CL, Whellan DJ, Lambe L, et al. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. J Cardiovasc Pharmacol. 2013;62:466–478.
  • Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13:11–27.
  • Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527–534.

• Pharmacodynamic study evaluating the transition between cangrelor and clopidogrel.

  • Dovlatova NL, Jakubowski JA, Sugidachi A, et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008;6:1153–1159.
  • Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7:435–442.

•• Pharmacodynamic study evaluating the transition between cangrelor and ticagrelor in patients with stable coronary artery disease.

  • Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26:42–48.

•• Pharmacodynamic study evaluating the transition between cangrelor and prasugrel in patients with stable coronary artery disease.

  • Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation. J Interv Cardiol. 2015;28:415–419.
  • Collet JP, Funck-Brentano C, Prats J, et al. Intravenous clopidogrel (MDCO-157) compared with oral clopidogrel: the randomized cross-over AMPHORE study. Am J Cardiovasc Drugs. 2015 [cited 2015 Sep 19]. doi:10.1007/s40256-015-0145-0.
  • Cushing DJ, Souney PF, Cooper WD, et al. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans: effects of intravenous clopidogrel. Clin Exp Pharmacol Physiol. 2012;39:3–8.
  • Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 2010;6:445–453.
  • Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012;5:336–346.
  • Angiolillo DJ, Welsh RC, Trenk D, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012;5:347–356.
  • Stone GW, Mehran R, Goldstein P, et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J Am Coll Cardiol. 2015;65:27–38.
  • Roffi M, Patrono C, Collet JP, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2015 [cited 2015 Aug 29]. doi:10.1093/eurheartj/ehv320.
  • Parodi G, Xanthopoulou I, Bellandi B, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65:511–512.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.